Nadeem Rais Explains: A Clinical Comparison of AntiPlatelets vs AntiCoagulants
Nadeem Rais, Clinical Pharmacist at NMC Healthcare, shared a post on LinkedIn:
“AntiPlatelets vs AntiCoagulants
Blood clot prevention is not one-size-fits-all. Two major drug classes act at different stages of thrombosis.
• 𝗔𝗻𝘁𝗶𝗣𝗹𝗮𝘁𝗲𝗹𝗲𝘁𝘀
Drugs that inhibit platelet activation and aggregation.
𝙈𝙚𝙘𝙝𝙖𝙣𝙞𝙨𝙢 𝙊𝙛 𝘼𝙘𝙩𝙞𝙤𝙣: They block platelet-to-platelet interaction at sites of vascular injury.
𝘾𝙤𝙢𝙢𝙤𝙣 𝘿𝙧𝙪𝙜𝙨:
▪ Aspirin (Acetylsalicylic Acid)
▪ Clopidogrel (Adenosine Diphosphate Receptor Inhibitor)
▪ Prasugrel (P2Y12 Receptor Inhibitor)
▪ Ticagrelor (Reversible P2Y12 Inhibitor)
𝙈𝙖𝙟𝙤𝙧 𝙄𝙣𝙙𝙞𝙘𝙖𝙩𝙞𝙤𝙣𝙨:
▪ Myocardial Infarction (Heart Attack)
▪ Ischemic Stroke
▪ Post Percutaneous Coronary Intervention (PCI)
𝙏𝙝𝙧𝙤𝙢𝙗𝙪𝙨 𝙏𝙮𝙥𝙚: Platelet-rich clots. Also called white clots.
𝙈𝙤𝙣𝙞𝙩𝙤𝙧𝙞𝙣𝙜: Routine laboratory monitoring is usually not required.
• 𝗔𝗻𝘁𝗶𝗖𝗼𝗮𝗴𝘂𝗹𝗮𝗻𝘁𝘀
Drugs that inhibit clotting factors in the coagulation cascade.
𝙈𝙚𝙘𝙝𝙖𝙣𝙞𝙨𝙢 𝙊𝙛 𝘼𝙘𝙩𝙞𝙤𝙣: They slow or stop fibrin formation.
𝘾𝙤𝙢𝙢𝙤𝙣 𝘿𝙧𝙪𝙜𝙨:
▪ Heparin (Indirect Thrombin Inhibitor)
▪ Warfarin (Vitamin K Antagonist)
▪ Dabigatran (Direct Thrombin Inhibitor)
▪ Rivaroxaban (Factor Xa Inhibitor)
▪ Apixaban (Factor Xa Inhibitor)
𝙈𝙖𝙟𝙤𝙧 𝙄𝙣𝙙𝙞𝙘𝙖𝙩𝙞𝙤𝙣𝙨:
▪ Deep Vein Thrombosis (DVT)
▪ Pulmonary Embolism (PE)
▪ Atrial Fibrillation (AF)
𝙏𝙝𝙧𝙤𝙢𝙗𝙪𝙨 𝙏𝙮𝙥𝙚: Fibrin-rich clots. Also called red clots.
𝙈𝙤𝙣𝙞𝙩𝙤𝙧𝙞𝙣𝙜:
▪ Warfarin requires International Normalized Ratio (INR) monitoring
▪ Direct Oral Anticoagulants usually do not require routine monitoring
𝗞𝗲𝘆 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗗𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲
→ AntiPlatelets act early at platelet level
→ AntiCoagulants act later at coagulation factor level
Credit: Federation of Clinical Pharmacists in India (FCPI)
Repost to share with your peers
Follow Nadeem Rais, PhD for more”
Follow the latest in Hemostasis Today.
-
May 23, 2026, 16:55Rahul Bhargava: Ensure Equal Recognition of Clinical Haematologists in Blood Cancer Clinical Trials
-
May 23, 2026, 16:44Brian O Mahony: World Haemophilia Day Receives Global WHO Recognition
-
May 23, 2026, 16:44Yusuf Hameed: Gene Therapy Could Reduce Lifetime Treatment Burden in Hemophilia A
-
May 23, 2026, 16:43Chokri Ben Lamine: Pacritinib Is a Key JAK Inhibitor for Cytopenic Myelofibrosis
-
May 23, 2026, 16:42Bartosz Hudzik: Bleeding Risk Alone Should Not Determine Treatment Intensity
-
May 23, 2026, 16:42Shimels Tessema: Celebrating the WHA Resolution on Hemophilia and Other Bleeding Disorders
-
May 23, 2026, 16:38José Octavio Alva Bucio: Securing the Future of Plasma and Blood-Derived Medicines
-
May 23, 2026, 16:33Why Are We Dismantling What Powers Humanity and the Global Economy? – ASH
-
May 23, 2026, 16:24Marc Wittwer: A Practical Viscoelastic-Guided Algorithm for Trauma-Induced Coagulopathy in Clinical Workflow